EuroPharma Today

J&J vs. Merck: The Race Is On As Incivek Passes First EU Regulatory Hurdle

Four days after the European Commission approved Merck & Co.'s protease inhibitor for hepatitis C, Victrelis (boceprevir), the European Medicines Agency has given the nod to its rival, Johnson & Johnson subsidiary Tibotec's Incivek (telaprevir).

With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks

With European Commission final approval granted on July 14 to Bristol-Myers Squibb Co.'s novel late-stage melanoma treatment Yervoy (ipilimumab), the company has now set its European pricing and reimbursement machinery into action.

European Commission Drops Boehringer Case And Lauds Itself For Receding Patent Abuse

On July 6, the European Commission announced that it had resolved its antitrust investigation into alleged weak patent filings by Boehringer Ingelheim GmbH.

AstraZeneca's Brilique Cleared In NICE's Initial Appraisal

AstraZeneca PLC's acute coronary syndrome therapy Brilique (ticagrelor) has received a preliminary thumbs up for use in the U.K.'s National Health Service by the country's National Institute for Health and Clinical Excellence (NICE).